Development History of the LigaSure Vessel Sealing System

Development History of the LigaSure Vessel Sealing System

---

I. Technology Origin and Market Introduction (1995–1999)

The LigaSure Vessel Sealing System (LVSS) was developed by Valleylab, Inc. (USA), later acquired by Tyco/Covidien and now part of Medtronic. It was first conceived in 1995 as a feedback‑controlled bipolar electrosurgical system—a major advancement over conventional bipolar devices.

Its core principle lies in real‑time impedance monitoring: the system automatically senses the tissue impedance between the jaws and instantly adjusts the delivered voltage and current. Combined with the mechanical pressure of the jaws, this causes denaturation of collagen and fibrin in the vessel wall, which fuse to form a translucent zone and create a permanent lumen seal. The seal can withstand pressures up to three times the normal human systolic blood pressure.

In 1998, the technology was officially launched on the market. The following year, the LigaSure™ 8 device made its debut as the world’s first energy‑based ligation system, marking a revolutionary step in surgical hemostasis. 1999 is widely regarded as the year when LigaSure’s “revolutionary” vessel‑sealing technology was introduced into general surgery.

---

II. Expansion into the Laparoscopic Era (2004–2010)

As the new century progressed, LigaSure quickly expanded into minimally invasive surgery.

· 2004 – The LigaSure™ V (with a dolphin‑head design) was released—the first 5‑mm laparoscopic instrument with an integrated blade. Its small diameter allowed it to pass through standard laparoscopic trocars, greatly broadening its use in minimally invasive procedures.

· 2008 – The LigaSure™ Blunt Tip device was introduced. In September of that year, the ForceTriad™ Energy Platform received SFDA (now NMPA) certification in China, becoming the core energy driver for LigaSure technology and further improving sealing consistency and efficiency.

· 2010 – The LigaSure™ Advance device joined the product portfolio.

During this phase, clinical applications expanded from open surgery to laparoscopic procedures across general surgery, urology, gynecology, and thoracic surgery.

---

III. Product Refinement and Technological Innovation (2012–2018)

In 2012, a new generation of the LigaSure Blunt Tip device featured a locking handle for improved stability and safety.

· 2014 was a significant year for product iteration. The first‑generation LigaSure™ Maryland jaw device was launched, featuring a curved jaw and one‑step activation. That same year, Covidien introduced two enhanced LigaSure products at the American College of Surgeons Clinical Congress. By then, nearly 20 years after its invention, LigaSure—together with the ForceTriad generator—had come to dominate the electrothermal bipolar vessel‑sealing market.

· 2016 – The LigaSure™ L‑hook device joined the family, equipped with a retractable monopolar hook.

· 2018 marked another technological leap: the new‑generation LigaSure Blunt Tip and Maryland jaw devices incorporated nanocoating technology, which reduced tissue sticking and improved procedural efficiency and seal consistency.

---

IV. Continuous Evolution and the Robotic Era (2023–Present)

· 2023 – The LigaSure™ XP Maryland jaw sealer‑divider was released, integrating the best features of all previous devices and elevating vessel‑sealing performance to new heights.

· 2025 – A landmark year: on July 21, Medtronic announced that LigaSure vessel‑sealing technology had received CE Mark approval for use with the Hugo™ robotic surgical system. The new LigaSure RAS Maryland instrument is the first robotic‑driven LigaSure device, powered by the Valleylab™ FT10 energy platform. It can seal and divide vessels up to 7 mm in diameter, as well as thick tissue and lymphatics, in approximately two seconds. At the end of 2024, Medtronic had already completed clinical trials with LigaSure RAS at several European medical centers.

---

V. Clinical Applications and Industry Impact

Over three decades of development, LigaSure has gained worldwide acceptance. As of 2025, the technology has been used in more than 35 million procedures across 65 countries, supported by over 1,300 clinical publications providing evidence‑based validation.

Clinically, numerous studies have demonstrated that LigaSure significantly reduces intraoperative blood loss, shortens operative time, decreases postoperative pain, and shortens hospital stays. It can safely seal vessels up to 7 mm in diameter and is applicable in general surgery, urology, vascular surgery, thoracic surgery, gynecology, and many other specialties.

From its conceptual birth in 1995, through the first product launch in 1999, to its entry into robotic surgery in 2025, LigaSure has evolved over thirty years from an “innovative hemostatic tool” into an industry standard, continuously advancing the safety and efficiency of surgical practice.